8,700 Studies Reviewed. 87.0% Found Biological Effects. The Evidence is Clear.
Shield Your Body
Immune System

Gupta V, Srivastava R

Bioeffects Seen

Authors not listed · 2024

Share:

IL-9 immune protein drives post-menopausal bone loss through inflammation, revealing targets for treatment.

Plain English Summary

Summary written for general audiences

Researchers studied how IL-9, an immune system protein, contributes to bone loss in post-menopausal osteoporosis using mice models. They found that estrogen loss increases IL-9 production, which accelerates bone breakdown by enhancing osteoclast cells that destroy bone tissue. The study suggests targeting IL-9 could offer new treatment approaches for post-menopausal bone loss.

Why This Matters

While this study doesn't directly examine EMF exposure, it provides crucial insight into inflammatory pathways that EMF research increasingly shows can be disrupted by electromagnetic fields. The science demonstrates that immune system dysfunction drives bone loss through specific cellular mechanisms - the same immune pathways that multiple studies show are affected by wireless radiation exposure. What this means for you is understanding that EMF exposure doesn't occur in isolation. Your body's inflammatory responses, including those affecting bone health, operate through interconnected systems that research suggests can be influenced by the electromagnetic environment around us. The reality is that as we learn more about how inflammation drives disease, we must consider all environmental factors that can trigger these pathways.

Exposure Information

Specific exposure levels were not quantified in this study.

Cite This Study
Unknown (2024). Gupta V, Srivastava R.
Show BibTeX
@article{gupta_v_srivastava_r_ce2397,
  author = {Unknown},
  title = {Gupta V, Srivastava R},
  year = {2024},
  doi = {10.1093/jbmrpl/ziae120},
  
}
DOI: 10.1093/jbmrpl/ziae120PubMed: 39399159

Quick Questions About This Study

IL-9 enhances osteoclastogenesis, the process where osteoclast cells form and break down bone tissue. When estrogen levels drop during menopause, IL-9 production increases, accelerating bone destruction and contributing to osteoporosis development.
Th9 and Th17 cells are the major producers of IL-9 after estrogen deprivation. These specialized immune cells increase their IL-9 secretion when estrogen levels decline, creating a cascade that promotes bone loss.
Yes, neutralizing IL-9 improved bone health in ovariectomized mice by inhibiting osteoclast function and reducing inflammatory cell activity. This suggests IL-9-targeted therapies could potentially treat post-menopausal osteoporosis in humans.
The study found that post-menopausal osteoporotic patients had increased IL-9-secreting Th9 cells compared to healthy controls, suggesting IL-9 plays a role in human osteoporosis development, not just in animal models.
IL-9 modulates the gut-immune-bone axis, affecting intestinal integrity alongside bone health. Blocking IL-9 maintained gut health while preventing bone loss, indicating this protein influences multiple interconnected body systems simultaneously.